Research
From the mechanism of resistance to the medicine that beats it
Our laboratory is dedicated to tackling one of the most pressing challenges in Oncology: drug resistance, including resistance to immunotherapies. At the heart of our mission lies a commitment to understanding the molecular and cellular mechanisms that drive resistance in cancer and other diseases. By deciphering these complex biological pathways, we aim to identify the key factors that limit the efficacy of current treatments.
To overcome these obstacles, we innovate at the intersection of nanomedicine and genomics. We design and engineer cutting-edge nanomaterials capable of delivering gene-editing tools and therapeutic agents directly to resistant cells. Our approach enables us to genetically inhibit resistance pathways and, in many cases, reverse drug resistance altogether, opening the door to more durable and curative therapies.
Our research is structured around three core pillars:
Mechanisms of Drug Resistance
We conduct in-depth investigations to unravel how cancer cells and other diseased tissues evade therapeutic interventions, including targeted drugs and immunotherapies.
Design of Novel Nanomaterials
We develop and optimize advanced nanocarriers and nanostructures tailored for precision delivery of genetic inhibitors and therapeutics, maximizing their impact while minimizing off-target effects.
In Vivo Validation in Animal Models
We rigorously test our strategies in animal models to establish proof-of-concept, evaluate efficacy, and understand the safety profile of our nanomedicine-based interventions.
Through the seamless integration of these pillars, our laboratory aspires to set new benchmarks in overcoming drug resistance, ultimately translating our discoveries into clinical solutions that improve patient outcomes.
Platforms & Technology
The nanoscale architectures we've engineered
Each platform pairs a delivery architecture with a therapeutic strategy — patented technologies that move from the bench toward the clinic.
Concentric Supraparticle
A self-assembled architecture in which nanoparticles organize into ordered concentric shells. Each layer can hold a distinct cargo, packing multiple agents into one stable, multilayered carrier.
Co-Silencing Nanoparticle
One particle, two payloads. By co-delivering siRNA against a drug-resistance gene and its compensatory backup, the platform shuts both pathways at once — leaving the tumor no easy escape route.
CRISPR / mRNA Nanocarrier
A lipid-based nanocarrier that shields mRNA and CRISPR machinery from degradation, ferries them across the cell membrane, and releases them where the edit needs to happen.